Shield Therapeutics plc Cash Flow Conversion Efficiency

Latest as of June 2025: 0.303x

Shield Therapeutics plc cash flow conversion efficiency. Based on the latest financial reports, Shield Therapeutics plc (STX) has a cash flow conversion efficiency ratio of 0.303x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.49 Million ≈ $-546.85 USD) by net assets (GBX-14.86 Million ≈ $-1.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Shield Therapeutics plc (2014–2024)

Cash flow conversion efficiency of Shield Therapeutics plc from 2014 to 2024. This chart illustrates how Shield Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Shield Therapeutics plc (STX) share price today for real-time trading data and today's change.

Shield Therapeutics plc Cash Flow Conversion Ratio Explained

Shield Therapeutics plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Shield Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shield Therapeutics plc ranked by their cash flow conversion efficiency. Also see Shield Therapeutics plc stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
ROBUS GROUP AS EO -60 F:LH2	N/A
GCL Global Holdings Ltd Warrants NASDAQ:GCLWW	-0.003x
Aloro Mining Corp V:AORO	0.005x
Longevity Health Holdings, Inc. NASDAQ:XAGE	0.070x
Fashion Bel Air S.A PA:ALFBA	0.029x
CENTAURUS ENERGY INC. F:72M0	-0.038x
LEGIBLE INC. F:D0T	N/A
H&G High Conviction Ltd AU:HCF	-0.275x

Annual Cash Flow Conversion Efficiency for Shield Therapeutics plc (2014–2024)

The table below shows the annual cash flow conversion efficiency of Shield Therapeutics plc from 2014 to 2024. Review cash generation quality of Shield Therapeutics plc to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX-1.05 Million ≈ $-127.95	GBX-7.01 Million ≈ $-852.49	6.663x	+500.42%
2023-12-31	GBX22.31 Million ≈ $2.71K	GBX-37.13 Million ≈ $-4.52K	-1.664x	+50.51%
2022-12-31	GBX5.43 Million ≈ $660.31	GBX-18.25 Million ≈ $-2.22K	-3.362x	-724.25%
2021-12-31	GBX41.03 Million ≈ $4.99K	GBX-16.74 Million ≈ $-2.04K	-0.408x	-782.15%
2020-12-31	GBX30.28 Million ≈ $3.68K	GBX-1.40 Million ≈ $-170.34	-0.046x	+63.44%
2019-12-31	GBX32.15 Million ≈ $3.91K	GBX-4.07 Million ≈ $-494.71	-0.126x	-2773.01%
2018-12-31	GBX40.43 Million ≈ $4.92K	GBX-178.00K ≈ $-21.66	-0.004x	+98.88%
2017-12-31	GBX41.21 Million ≈ $5.01K	GBX-16.15 Million ≈ $-1.97K	-0.392x	-84.95%
2016-12-31	GBX48.40 Million ≈ $5.89K	GBX-10.26 Million ≈ $-1.25K	-0.212x	-194.45%
2015-12-31	GBX-18.64 Million ≈ $-2.27K	GBX-4.18 Million ≈ $-508.95	0.224x	+22.79%
2014-12-31	GBX-18.28 Million ≈ $-2.22K	GBX-3.34 Million ≈ $-406.50	0.183x	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$415.82K

GBX3.42 Billion GBX

Market Cap Rank

#31127 Global

#943 in UK

Share Price

GBX3.20

Change (1 day)

-3.03%

52-Week Range

GBX3.05 - GBX12.20

All Time High

GBX185.02